Skip to main content
SpringerLink
Log in
Book cover

Ovarian Stimulation Protocols pp 103–111Cite as

Ovarian Stimulation for PCO Patients and Management of OHSS

  • Chapter

  • 1216 Accesses

Abstract

Polycystic ovary syndrome (PCOS) has been implicated as a main endocrine disorder that can cause oligo- or anovulation. PCOS has been studied for a long period and was first described by Stein and Leventhal in 1935.

A consensus between the European Society for Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) defined the diagnosis criteria for PCOS as oligo- and/or anovulation, hyperandrogenism (clinical and/or biochemical), and the appearance of polycystic ovaries on ultrasound. Most PCOS cases can be diagnosed using these criteria; however, there are some variant phenotypes, and the diagnosis is often difficult. Although PCOS has been well studied, an optimal treatment to achieve pregnancy remains unclear. In this chapter, the current status of PCOS and management methods of the disorder are discussed. Furthermore, how to control ovarian hyperstimulation syndrome (OHSS), the most troublesome side effect of PCOS during ovarian stimulation, is discussed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181–91.

    Google Scholar 

  2. Arora S, Allahbadia GN. Early origins of polycystic ovary syndrome. In: Allahbadia GN, Agrawal R, editors. Polycystic ovary syndrome. Kent: Anshan Ltd; 2007. p. 3–12.

    Google Scholar 

  3. Gharani N, Gharani N, Waterworth DM, et al. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet. 1997;6:397–402.

    Article  CAS  PubMed  Google Scholar 

  4. Lie FS, Schipper I, de Jong FH, Themmen AP, Visser JA, Laven JS. Serum anti-Müllerian hormone and inhibin B concentrations are not useful predictors of ovarian response during ovulation induction treatment with recombinant follicle-stimulating hormone in women with polycystic ovary syndrome. Fertil Steril. 2011;96:459–63.

    Article  Google Scholar 

  5. Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S, Mason H. Granulosa cell production of anti-mullerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab. 2007;92:240–5.

    Article  CAS  PubMed  Google Scholar 

  6. Lass A, Skull J, McVeigh E, Margara R, Winston R. Measurement of ovarian volume by transvaginal sonography before ovulation induction with human menopausal gonadotrophin for in-vitro fertilization) can predict poor response. Hum Reprod. 1997;12:294–7.

    Article  CAS  PubMed  Google Scholar 

  7. Holte J, Brodin T, Berglund L, Hadziosmanovic N, Olovsso M, Bergh T. Antral follicle counts are strongly associated with live-birth rates after assisted reproduction, with superior treatment outcome in women with polycystic ovaries. Fertil Steril. 2011;96:594–9.

    Article  PubMed  Google Scholar 

  8. Imani B, Eijkemans MJ, te Velde ER, Habbema JD, Fauser BC. A nomogram to predict the probability of live birth after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Fertil Steril. 2002;77:91–7.

    Article  PubMed  Google Scholar 

  9. Abu Hashim H, Bazeed M, Abd EI. Minimal stimulation or clomiphene citrate as first-line therapy in women with polycystic ovary syndrome: a randomized controlled trial. Gynecol Endocrinol. 2012;28:87–90.

    Article  CAS  PubMed  Google Scholar 

  10. National Collaborating Centre for Women’s and Children’s Health/National Institute for Clinical Excellence. Fertility: assessment and treatment for people with fertility problems, Clinical guideline, vol. II. London: RCOG Press; 2004.

    Google Scholar 

  11. Homburg R, Hendriks ML, König TE, Anderson RA, Balen AH, Brincat M, Hompes P, Lambalk CB, et al. Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study. Hum Reprod. 2012;27:468–73.

    Article  CAS  PubMed  Google Scholar 

  12. Homburg R. Oral agents for ovulation induction-clomiphene citrate versus aromatasc inhibitors. Hum Fertil (Camb). 2008;11:17–22.

    Article  CAS  Google Scholar 

  13. Rahmani E, Ahmadi S, Motamed N, Maneshi HO. Dosage optimization for letrozole treatment in clomiphene-resistant patients with polycystic ovary syndrome: a prospective interventional study. Obstet Gynecol Int. 2012;2012:758508.

    Article  PubMed Central  PubMed  Google Scholar 

  14. He D, Jiang F. Meta-analysis of letrozole versus clomiphene citrate in polycystic ovary syndrome. Reprod Biomed Online. 2012;23:91–6.

    Article  Google Scholar 

  15. Dhaliwal LK, Suri V, Gupta KR, Sahdev S. Tamoxifen: an alternative to clomiphene in women with polycystic ovary syndrome. J Hum Reprod Sci. 2011;4:76–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Cook LS, Weiss NS, Schwartz SM. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial and breast cancers. J Natl Cancer Inst. 1995;87:1359–64.

    Article  CAS  PubMed  Google Scholar 

  17. de Paula Guedes Neto E, Savaris RF, von Eye Corleta H, de Moraes GS, de Amaral Cristovam R, Lessey BA. Prospective, randomized comparison between raloxifene and clomiphene citrate for ovulation induction in polycystic ovary syndrome. Fertil Steril. 2011;96:769–73.

    Article  PubMed  Google Scholar 

  18. Abuzeid MI, Mitwally M, Abuzeid YM, Bokhari HA, Ashraf M, Diamond MP. Early initiation of gonadotropin-releasing hormone antagonist in polycystic ovarian syndrome patients undergoing assisted reproduction: randomized controlled trial. J Assist Reprod Genet. 2012;29:1193–202.

    Article  PubMed Central  PubMed  Google Scholar 

  19. Ashrafi M, Kiani K, Ghasemi A, Rastegar F, Nabavi M. The effect of low dose human chorionic gonadotropin on follicular response and oocyte maturation in PCOS patients undergoing IVF cycles: a randomized clinical trial of efficacy and safety. Arch Gynecol Obstet. 2011;284:1431–8.

    Article  CAS  PubMed  Google Scholar 

  20. Nargund G, Hutchison L, Scaramuzzi R, Campbell S. Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of JVP cycles. Reprod Biomed Online. 2007;14:682–5.

    Article  CAS  PubMed  Google Scholar 

  21. Pincus G, Enzmann EV. The comparative behavior of mammalian eggs in vivo and in vitro: I. The activation of ovarian eggs. J Exp Med. 1935;62:655–75.

    Article  Google Scholar 

  22. Edwards R. Maturation in vitro of mouse, sheep, cow, pig, rhesus monkey and human ovarian oocytes. Nature. 1965;20:349–51.

    Article  Google Scholar 

  23. Edwards R, Bavister B, Steptoe P. Early stages of fertilization in vitro of human oocytes matured in vitro. Nature. 1969;221:632–5.

    Article  CAS  PubMed  Google Scholar 

  24. Veeck LL, Wortham Jr JW, Witmyer J, et al. Maturation and fertilization of morphologically immature human oocytes in a program of in vitro fertilization. Fertil Steril. 1983;39:594–602.

    CAS  PubMed  Google Scholar 

  25. Cha KY, Koo JJ, Ko JJ, et al. Pregnancy after in vitro fertilization of human follicular oocytes collected from nonstimulated cycles, their culture in vitro and their transfer in a donor oocyte program. Fertil Steril. 1991;55:109–13.

    CAS  PubMed  Google Scholar 

  26. Chian RC, Buckett WM, Tulandi T, Tan SL. Prospective randomized study of human chorionic gonadotrophin priming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome. Hum Reprod. 2000;15:165–70.

    Article  CAS  PubMed  Google Scholar 

  27. Gremeau AS, Andreadis N, Fatum M, Craig J, Turner K, McVeigh E, et al. In vitro maturation or in vitro fertilization for women with polycystic ovaries? A case-control study of 194 treatment cycles. Fertil Steril. 2012;98:355–60.

    Article  PubMed  Google Scholar 

  28. Smitz J, Camus M, Devroey P, Erard P, Wisanto A, Van Steirteghem AC. Incidence of severe ovarian hyperstimulation syndrome after GnRH agonist/HMG superovulation for in vitro fertilization. Hum Reprod. 1990;5:933–7.

    CAS  PubMed  Google Scholar 

  29. Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernandez ER. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril. 2006;86:1682–7.

    Article  CAS  PubMed  Google Scholar 

  30. Martinez F, Rodriguez DB, Buxaderas R, Tur R, Mancini F, et al. GnRH antagonist rescue of a long-protocol IVF cycle and GnRH agonist trigger to avoid ovarian hyperstimulation syndrome: three case reports. Fertil Steril. 2011;95:2432 e17–9.

    Article  PubMed  Google Scholar 

  31. Youssef MA, Al-Inany HG, Aboulghar M, Mansour R, Abou-Setta AM. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database Syst Rev. 2011;(4):CD003719.

    Google Scholar 

  32. Ohata Y, Harada T, Ito M, Yoshida S, Iwabe T, Terakawa N. Coasting may reduce the severity of the ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome. Gynecol Obstet Invest. 2000;50:186–8.

    Article  CAS  PubMed  Google Scholar 

  33. Seow KM, Lin YH, Bai CH, Chen HJ, Hsieh BC, Huang L, et al. Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: a randomized controlled trial. Reprod Biomed Online. 2013;26:562–8.

    Article  CAS  PubMed  Google Scholar 

  34. Guventag Guven ES, Dilbaz S, Duraker R, Mentese A, Cinar O, Ozdegirmenci O. The effect of cabergoline on follicular microenvironment profile in patients with high risk of OHSS. Gynecol Endocrinol. 2013;29:749–53.

    Article  Google Scholar 

  35. Esinler I, Bozdag G, Karakocsokmensuer L. Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting. Arch Gynecol Obstet. 2013;288(5):1159–63.

    Article  CAS  PubMed  Google Scholar 

  36. Gomez R, Soares SR, Busso C, Garcia-Velasco JA, Simon C, et al. Physiology and pathology of ovarian hyperstimulation syndrome. Semin Reprod Med. 2010;28:448–57.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, IVF Namba Clinic, Kansai Medical University, 1-17-28, Minami-horie, Nishi-ku, Osaka, 550-0015, Japan

    Yoshiharu Morimoto MD, PhD

Authors
  1. Yoshiharu Morimoto MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshiharu Morimoto MD, PhD .

Editor information

Editors and Affiliations

  1. 1st floor, Rotunda-CHR 36, Mumbai, India

    Gautam N. Allahbadia

  2. IVF Namba Clinic, Osaka, Japan

    Yoshiharu Morimoto

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer India

About this chapter

Cite this chapter

Morimoto, Y. (2016). Ovarian Stimulation for PCO Patients and Management of OHSS. In: Allahbadia, G., Morimoto, Y. (eds) Ovarian Stimulation Protocols. Springer, New Delhi. https://doi.org/10.1007/978-81-322-1121-1_8

Download citation

  • DOI: https://doi.org/10.1007/978-81-322-1121-1_8

  • Publisher Name: Springer, New Delhi

  • Print ISBN: 978-81-322-1120-4

  • Online ISBN: 978-81-322-1121-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation